Interstitial Lung Disease
US PARTNER
An Introduction to Interstitial Lung Disease
Ongoing translational research is unearthing targetable mechanisms of disease
progression shared across the spectrum of interstitial lung diseases (ILDs). Recent approvals of antifibrotic therapies slowing loss of lung function have advanced treatment and care options for patients living with progressive ILD. Immunomodulatory agents inhibiting immune-mediated pathways (including interleukin (IL)-6-driven inflammation and adaptive immune cell responses) are currently undergoing
evaluation for disease modifying properties to preserve lung function in ILD with underlying autoimmune disease.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Boehringer Ingelheim has announced that its investigational drug, nerandomilast (BI 1015550), has successfully met the primary endpoint in the phase III FIBRONEER™-ILD study. The trial assessed the absolute change from baseline in forced vital capacity (FVC) [mL] at Week 52 compared ...
Although there is limited evidence on the link between interstitial lung disease (ILD) and malnutrition, malnourished patients tend to have shorter survival rates, regardless of disease severity. A late-breaking abstract presented at ERS 2024 titled “Dietetic intervention in malnourished patients with interstitial lung disease (ILD): a pilot trial” investigated whether dietitian involvement could provide meaningful benefits to these patients, potentially laying the groundwork for further research and future clinical guidelines.
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders characterized by inflammation and/or fibrosis.1 Pulmonary fibrosis develops due to repeated cycles of injury and impaired repair with fibroblast activation and migration with the resultant deposition of extracellular matrix ...
Interstitial lung disease (ILD) frequently complicates rheumatoid arthritis (RA).1 Moreover, it is more common among those who are male, smoke or are seropositive and with increasing age.1 Emergent risk factors include gain-of-function promoter variants in the MUC5B gene and ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
